
    
      Part I of the study will consist of a single-dose, open-label, randomized, four-way cross
      over study with topical administration of etoricoxib gel on the knee of osteoarthritis
      participants. The washout between successive dose administrations will be at least one week.
      Part 2 of the study will consist of double-blind, randomized, placebo-controlled, parallel
      groups, multiple dose, twice daily topical administration of etoricoxib or placebo gel on the
      knee of osteoarthritis participants for a period of two weeks.
    
  